Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNXU NASDAQ:LNSR NASDAQ:PROF NASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNXUConexeu Sciences$9.23+3.9%$11.96$8.14▼$18.79$246.98MN/A101,455 shs36,689 shsLNSRLENSAR$5.76-0.7%$5.86$5.06▼$13.43$70.73M0.8787,137 shs409 shsPROFProfound Medical$6.83+0.3%$6.83$3.76▼$8.95$248.93M0.73158,969 shs1,222 shsTLSITriSalus Life Sciences$4.28-0.7%$3.79$2.20▼$7.95$262.88M0.43313,095 shs38,683 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNXUConexeu Sciences-9.66%-14.12%-33.13%+887,999,900.00%+887,999,900.00%LNSRLENSAR-0.86%-1.20%+0.17%+7.48%-56.11%PROFProfound Medical-0.58%-4.76%-0.87%-0.44%+20.74%TLSITriSalus Life Sciences+0.47%+1.89%+5.64%-4.86%-6.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNXUConexeu Sciences$9.23+3.9%$11.96$8.14▼$18.79$246.98MN/A101,455 shs36,689 shsLNSRLENSAR$5.76-0.7%$5.86$5.06▼$13.43$70.73M0.8787,137 shs409 shsPROFProfound Medical$6.83+0.3%$6.83$3.76▼$8.95$248.93M0.73158,969 shs1,222 shsTLSITriSalus Life Sciences$4.28-0.7%$3.79$2.20▼$7.95$262.88M0.43313,095 shs38,683 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNXUConexeu Sciences-9.66%-14.12%-33.13%+887,999,900.00%+887,999,900.00%LNSRLENSAR-0.86%-1.20%+0.17%+7.48%-56.11%PROFProfound Medical-0.58%-4.76%-0.87%-0.44%+20.74%TLSITriSalus Life Sciences+0.47%+1.89%+5.64%-4.86%-6.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNXUConexeu Sciences 2.50Moderate Buy$20.00116.68% UpsideLNSRLENSAR 2.33Hold$10.0073.61% UpsidePROFProfound Medical 2.00Hold$12.0075.67% UpsideTLSITriSalus Life Sciences 2.25Hold$7.5075.23% UpsideCurrent Analyst Ratings BreakdownLatest LNSR, CNXU, PROF, and TLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/29/2026CNXUConexeu Sciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/26/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/22/2026CNXUConexeu Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.006/11/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026TLSITriSalus Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026TLSITriSalus Life Sciences Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.005/11/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/7/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNXUConexeu SciencesN/AN/AN/AN/AN/AN/ALNSRLENSAR$58.44M1.21N/AN/A($2.18) per share-2.64PROFProfound Medical$16.10M15.42N/AN/A$1.83 per share3.73TLSITriSalus Life Sciences$45.15M5.82N/AN/A($0.68) per share-6.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNXUConexeu SciencesN/A-$0.11N/AN/AN/AN/AN/AN/AN/ALNSRLENSAR-$34.28M-$0.58N/AN/AN/A50.94%-183.19%42.26%8/6/2026 (Estimated)PROFProfound Medical-$42.57M-$1.24N/AN/AN/A-206.76%-78.88%-64.06%8/6/2026 (Estimated)TLSITriSalus Life Sciences-$39.23M-$1.41N/AN/AN/A-60.85%N/A-69.91%8/6/2026 (Estimated)Latest LNSR, CNXU, PROF, and TLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026LNSRLENSAR-$0.1650N/AN/AN/A$14.65 millionN/A8/6/2026Q2 2026PROFProfound Medical-$0.22N/AN/AN/A$4.75 millionN/A8/6/2026Q2 2026TLSITriSalus Life Sciences-$0.1550N/AN/AN/A$10.27 millionN/A6/15/2026Q2 2026CNXUConexeu SciencesN/A-$0.11N/A-$0.11N/AN/A5/8/2026Q1 2026LNSRLENSAR$0.1850$1.56+$1.3750N/A$13.40 million$13.43 million5/7/2026Q1 2026PROFProfound Medical-$0.24-$0.19+$0.05$0.19$4.85 million$5.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNXUConexeu SciencesN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNXUConexeu SciencesN/AN/AN/ALNSRLENSARN/A2.381.08PROFProfound MedicalN/A6.565.71TLSITriSalus Life Sciences2.585.785.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNXUConexeu SciencesN/ALNSRLENSAR40.15%PROFProfound Medical47.86%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipCNXUConexeu SciencesN/ALNSRLENSAR65.80%PROFProfound Medical1.52%TLSITriSalus Life Sciences16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNXUConexeu Sciences426.76 millionN/AN/ALNSRLENSAR11012.28 million4.20 millionOptionablePROFProfound Medical15036.34 million35.79 millionOptionableTLSITriSalus Life Sciences10661.42 million51.41 millionNot OptionableLNSR, CNXU, PROF, and TLSI HeadlinesRecent News About These CompaniesTriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference CallJuly 16, 2026 | businesswire.comPerkins Capital Management Inc. Buys Shares of 230,101 TriSalus Life Sciences, Inc. $TLSIJuly 1, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 25, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 23, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 18, 2026 | prnewswire.comTLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law FirmJune 17, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 16, 2026 | globenewswire.comTLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law FirmJune 11, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 11, 2026 | prnewswire.comTriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver CancerJune 10, 2026 | finance.yahoo.comWhy TriSalus Life Sciences, Inc.’s (TLSI) Stock Is Up 5.09%June 10, 2026 | aaii.comATLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law FirmJune 10, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 9, 2026 | globenewswire.comTLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law FirmJune 8, 2026 | prnewswire.comTLSI INVESTOR ALERT: Holzer & Holzer, LLC Investigation of TriSalus Life Sciences, Inc.June 5, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 4, 2026 | prnewswire.comTLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law FirmJune 3, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 2, 2026 | globenewswire.comTLSI ALERT: Levi & Korsinsky Investigates TriSalus Life Sciences, Inc. on Behalf of Shareholders Who Lost MoneyMay 24, 2026 | newsfilecorp.comNTLSI (TLSI) Securities Fraud Investigation - Levi & KorsinskyMay 22, 2026 | prnewswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...May 20, 2026 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesUSA Today's Digital Revival Is Gaining Steam, But With Plenty of RiskBy Peter Frank | June 22, 2026This Single Factor Is Holding Back Carvana’s Disruptive EdgeBy Chris Markoch | June 26, 2026Capri's Turnaround Is Taking Shape, But Is the Stock a Buy Yet?By Jennifer Ryan Woods | June 28, 2026Why Exxon Could Be the Market's Next Big Comeback StockBy Thomas Hughes | July 8, 2026PepsiCo’s Dividend Could Turn Patience Into Real ProfitBy Thomas Hughes | July 10, 2026LNSR, CNXU, PROF, and TLSI Company DescriptionsConexeu Sciences NASDAQ:CNXU$9.23 +0.35 (+3.94%) As of 11:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.LENSAR NASDAQ:LNSR$5.76 -0.04 (-0.69%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Profound Medical NASDAQ:PROF$6.83 +0.02 (+0.31%) As of 11:19 AM Eastern This is a fair market value price provided by Massive. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.TriSalus Life Sciences NASDAQ:TLSI$4.28 -0.03 (-0.70%) As of 11:19 AM Eastern This is a fair market value price provided by Massive. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? IBM Just Had Its Worst Day Ever—What Earnings Must Prove AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Oracle Is One Step From Junk—Can It Afford the AI Boom? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
